Premier Path Wealth Partners LLC Sells 90 Shares of Zoetis Inc. (NYSE:ZTS)

Premier Path Wealth Partners LLC lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.6% in the fourth quarter, HoldingsChannel reports. The firm owned 5,388 shares of the company’s stock after selling 90 shares during the period. Premier Path Wealth Partners LLC’s holdings in Zoetis were worth $878,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Mercer Global Advisors Inc. ADV boosted its stake in shares of Zoetis by 12.3% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 49,298 shares of the company’s stock worth $8,530,000 after acquiring an additional 5,384 shares during the period. GM Advisory Group LLC acquired a new stake in Zoetis during the 2nd quarter valued at $243,000. Canada Pension Plan Investment Board boosted its position in Zoetis by 7.7% during the second quarter. Canada Pension Plan Investment Board now owns 688,738 shares of the company’s stock worth $119,400,000 after purchasing an additional 49,386 shares during the period. Callan Capital LLC increased its holdings in shares of Zoetis by 7.1% in the second quarter. Callan Capital LLC now owns 2,688 shares of the company’s stock valued at $466,000 after purchasing an additional 178 shares during the last quarter. Finally, AE Wealth Management LLC raised its position in shares of Zoetis by 9.5% in the second quarter. AE Wealth Management LLC now owns 1,988 shares of the company’s stock valued at $345,000 after purchasing an additional 172 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $166.01 on Friday. The stock’s fifty day moving average price is $170.93 and its two-hundred day moving average price is $179.95. The firm has a market cap of $74.90 billion, a PE ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter last year, the business earned $1.36 earnings per share. Zoetis’s revenue was up 11.6% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 5.91 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.20%. Zoetis’s payout ratio is presently 32.52%.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.